Recruiting

Observational Study

Sponsor:

Massachusetts General Hospital

Code:

NCT05124392

Conditions

CJD (Creutzfeldt Jakob Disease)

Prion Diseases

GSS

FFI

Familial Fatal Insomnia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.

Conditions

CJD (Creutzfeldt Jakob Disease)

Prion Diseases

GSS

FFI

Familial Fatal Insomnia

Study ID

NCT05124392

Start date

Dec 1, 2017

Status verified date

Aug, 2026

Completion date

Jun 1, 2027

Anticipated

Primary completion date

Jun 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Aged 18 - 85,
2. One of the following:

  • a. Known carrier of pathogenic PRNP mutation
  • b. History of probable or definite prion disease in biological parent and other family members
  • c. Non-carrier family members and/or unrelated previously enrolled negative control volunteers
3. Medically safe to undergo blood draw, lumbar puncture and cognitive testing,
4. Adequate visual and auditory acuity to complete cognitive testing,
5. Fluent in English,
6. At least 5 years of education,
7. Capable of providing informed consent and following study procedures,

Exclusion Criteria:

1. Any CNS disease other than asymptomatic or early prion disease, such as clinical stroke, brain tumor, multiple sclerosis, significant head trauma with persistent neurological or neurocognitive deficits, Alzheimer's disease, Parkinson's disease, frontotemporal lobar degeneration or other known neurodegenerative disease,
2. History of alcohol or other substance abuse or dependence within the past two years,
3. Any significant systemic illness or unstable medical condition or pregnancy that could represent safety risk or affect participation in the study,
4. Coagulopathy or anti-coagulant therapy (such as Coumadin) increasing the risk for phlebotomy or lumbar puncture resulting in PT/PTT and INR within 1.5 standard deviation over the upper normal limit.

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Arms

Individuals with a family history of Prion disease

Individuals with a family history of Prion disease

Primary outcome measure

  • CSF YKL40 [ Time Frame: 1 year ]
  • CSF Tau [ Time Frame: 1 year ]
  • CSF Nfl [ Time Frame: 1 year ]
  • CSF GFAP [ Time Frame: 1 year ]
  • CSF Prion protein [ Time Frame: 1 year ]
  • CSF Prion biomarkers [ Time Frame: 1 year ]
  • Cognition [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Locations

Alzheimer's Clinical and Translational Research Unit

Recruiting

Charlestown, Massachusetts, United States, 02129

Contacts

Principal Investigator:

Steven E Arnold, MD

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Aug 13, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-03. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-08-13. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.